|The power and limitations of immunobridging studies: the example of COVID-19 vaccines|
|Chair: Hanna Nohynek,
Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee
Bridging studies – why and how?
Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
Panel discussion: Strategies behind the variant adapted COVID-19 vaccines development
The power and limitations of immunobridging studies: the example of COVID-19 vaccines